本帖最后由 老马 于 2012-1-13 21:20 编辑 " ?6 p: y% N- [
% U$ C! d+ e5 g. v8 T爱必妥和阿瓦斯丁的比较6 \9 r5 p& H: L) H
1 q' l% \5 q/ H2 ?1 ?3 d& ~http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
3 ]* ~& @3 u- T' L
3 Q) c6 Z! X( @8 }
; C4 G0 I8 m' T' b2 k' mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% I8 _" U' H" z! B# k' u# C& u( x
==================================================$ {4 x8 X: D* P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- Y! G, H2 D! y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& A* S& c& d. n$ I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( P# X: C0 p' Y0 o7 M5 _; J0 |
|